Skip to content
Facebook Twitter Linkedin
InMed-logo-01
  • Pharmaceutical
    • Cannabinoids in Development
    • INM-755 for Epidermolysis Bullosa
    • INM-088 for Glaucoma
    • INM-900 Series for Neurodegenerative Disease
    • Novel Cannabinoid Analogs
  • Manufacturing
    • BayMedica – Rare Cannabinoid Ingredients
    • Cannabinoid Manufacturing Expertise
    • IntegraSyn™ Cannabinoid Manufacturing
  • Investors
    • News Releases
    • Events
    • Stock Information
    • Corporate Governance
    • Financials & AGM Materials
    • Filings
    • Presentations
    • Media and Videos
    • Investor Contact
  • Corporate
    • Management
    • Board of Directors
    • Scientific Advisors
    • Partners and Collaborators
    • Careers
    • Contact
  • Learn
    • What is Cannabinol (CBN)?
    • What is Epidermolysis Bullosa (EB)?
    • What is Glaucoma?
    • Cannabinoid Manufacturing Economics 101
    • GMP Manufacturing Standards by Product Type
    • Cannabis Treatments for Glaucoma
    • Cannabinoid Science
    • Articles and Videos
Menu
  • Pharmaceutical
    • Cannabinoids in Development
    • INM-755 for Epidermolysis Bullosa
    • INM-088 for Glaucoma
    • INM-900 Series for Neurodegenerative Disease
    • Novel Cannabinoid Analogs
  • Manufacturing
    • BayMedica – Rare Cannabinoid Ingredients
    • Cannabinoid Manufacturing Expertise
    • IntegraSyn™ Cannabinoid Manufacturing
  • Investors
    • News Releases
    • Events
    • Stock Information
    • Corporate Governance
    • Financials & AGM Materials
    • Filings
    • Presentations
    • Media and Videos
    • Investor Contact
  • Corporate
    • Management
    • Board of Directors
    • Scientific Advisors
    • Partners and Collaborators
    • Careers
    • Contact
  • Learn
    • What is Cannabinol (CBN)?
    • What is Epidermolysis Bullosa (EB)?
    • What is Glaucoma?
    • Cannabinoid Manufacturing Economics 101
    • GMP Manufacturing Standards by Product Type
    • Cannabis Treatments for Glaucoma
    • Cannabinoid Science
    • Articles and Videos

In the Media

  • February 3, 2022

Cannabinoids See Explosive Growth Opportunity | The Dales Report

BayMedica’s VP of Commercial Operations, Chris Meiering, joins Shadd Dales of The Dales Report to talk about the growth opportunities in the cannabinoid industry.

In the interview, Chris talks about how the cannabinoids industry is maturing and the big changes he expects to see in the market. With the saturation of CBD products, Chris talks about the opportunities of rare cannabinoids as a differentiator and being able to offer something unique. He talks about how modern manufacturing methods make these minor cannabinoids, which were too difficult to get from plant extraction, are now cost effective for the consumer health and wellness industry.

Chris talks about the importance of a regulatory framework for the industry to ensure no medical claims are made without proven therapeutic benefit through clinical trials. He also talks InMed and BayMedica’s cannabinoid pharmaceutical, manufacturing and commercial programs, making them well-positioned for the cannabinoid industry’s growth.

Full Article
Source: The Dales Report

Share this post

Latest Articles

What quality controls should be put in place to ensure consistency and purity of cannabinoids for CPG products?

Dr. Shane Johnson, GM of BayMedica, InMed’s subsidiary, answers these questions: What is the minimum GMP standard that consumers should expect? What quality controls should

Read More
August 18, 2023

What makes cannabinoids an interesting pharmaceutical target?

Dr. Shane Johnson, GM of BayMedica, InMed’s subsidiary, answers these questions: What is the role of the endocannabinoid system? How do cannabinoids interact with the

Read More
August 18, 2023

What is the difference between illegal synthetics and bioidentical synthesized cannabinoids?

Dr. Shane Johnson, GM of BayMedica, InMed’s subsidiary, answers these questions: What are illegal synthetic cannabinoids? How are illegal synthetic cannabinoids different from bioidentical synthesized

Read More
July 18, 2023
InMed-logo-mono
#310 – 815 West Hastings St.
Vancouver, BC, Canada
V6C 1B4

Pharmaceutical

  • Cannabinoids in Development
  • INM-755 for Epidermolysis Bullosa
  • INM-088 for Glaucoma
  • INM-900 Series for Neurodegenerative Disease
  • Novel Cannabinoid Analogs

MANUFACTURING

  • BayMedica – Rare Cannabinoid Ingredients
  • Cannabinoid Manufacturing Expertise
  • IntegraSyn™ Cannabinoid Manufacturing

Investor

  • News
  • Events
  • Stock Information
  • Corporate Governance
  • Financials & AGM Materials
  • Filings
  • Presentations
  • Media & Videos
  • Investor Contact

CORPORATE

  • Management
  • Board of Directors
  • Scientific Advisors
  • Partners and Collaborators
  • Careers
  • Contact

Learn

  • What is Cannabinol (CBN)?
  • What is Epidermolysis Bullosa (EB)?
  • What is Glaucoma?
  • Cannabinoid Manufacturing Economics 101
  • GMP Manufacturing Standards by Product Type
  • Cannabinoids for Glaucoma
  • Cannabinoid Science
  • Articles and Videos

© Copyright 2023 InMed Pharmaceuticals Inc.

  • Privacy Policy
  • Terms of Use
  • Legal Disclaimer
  • Find Us On:
Subscribe

Sign up to receive emails from InMed Pharmaceuticals

"*" indicates required fields

Name*
Consent*